Traveka Wealth
ABBV icon

Traveka Wealth’s AbbVie ABBV Stock Holding History

Traveka Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$989K Buy
3,781
+50
+1% +$12.8K 0.31% 63
2026
Q2 		$939K Buy
3,731
+83
+2% +$17.9K 0.31% 65
2026
Q1 		$793K Buy
3,648
+27
+0.7% +$5.99K 0.3% 64
2025
Q4 		$827K Sell
3,621
-449
-11% -$102K 0.34% 58
2025
Q3 		$942K Buy
4,070
+76
+2% +$15.5K 0.42% 45
2025
Q2 		$741K Buy
3,994
+66
+2% +$12.3K 0.39% 48
2025
Q1 		$823K Buy
3,928
+23
+0.6% +$4.47K 0.46% 45
2024
Q4 		$694K Buy
3,905
+1,668
+75% +$307K 0.38% 52
2024
Q3 		$442K Buy
2,237
+83
+4% +$15.5K 0.22% 64
2024
Q2 		$369K Buy
2,154
+70
+3% +$11.6K 0.18% 70
2024
Q1 		$379K Sell
2,084
-1,875
-47% -$323K 0.18% 66
2023
Q4 		$614K Buy
+3,959
New +$577K 0.31% 51

Other funds holding ABBV

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Traveka Wealth's ABBV Position: Q3 2026 in Review

Traveka Wealth increased its AbbVie (ABBV) stake by 1.3% in Q3 2026, buying an estimated $12.8K and bringing the position to 3,781 shares worth $989K. The position accounts for 0.31% of the portfolio, ranked #63.

Traveka Wealth first reported a position in ABBV in Q4 2023 and has held it in 12 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Traveka Wealth held 3,781 shares of AbbVie worth $989K as of Q3 2026.
  • Traveka Wealth bought 50 AbbVie shares in Q3 2026, an estimated $12.8K.
  • AbbVie made up 0.31% of Traveka Wealth's portfolio in Q3 2026, its #63 holding.
  • Traveka Wealth first reported a position in AbbVie in Q4 2023 and has held it in 12 quarters since.
  • 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Traveka Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.